GSE122710
Next generation sequencing of human hepatic stellate cell line, LX-2 treated with recombinant human TGF-ß1, with DMSO or ML290 (5 µM) for 72h.
The overall aim of this experiment was to identify specific genes and molecular pathways regulated by ML290, a small molecule agonist of the relaxin receptor, RXFP1, in the context of liver fibrosis. Overall design: Whole transcriptome mRNA sequencing of transformed LX-2 cells using HiSeq platforms with paired-end 150 bp (PE 150) sequencing strategy, with four biological replicates in each treatment group.